About The Program
The MIND program consists of multiple clinical trials that are evaluating tafasitamab and another drug called parsaclisib as part of different treatment strategies for patients with NHL or chronic lymphocytic leukemia (CLL). Two trials were recently initiated to evaluate the safety and efficacy of these 2 drugs for people with NHL or CLL who have already tried other treatment options.
02
About the Disease
What is the disease?
Non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) are types of cancer that start in the body’s white blood cells, which are also known as “lymphocytes.”
What are the symptoms?
NHL and CLL share many symptoms, including swollen lymph nodes, abdominal pain, fatigue, fever, night sweats, and weight loss.6,7
What causes the disease?
NHL usually starts in white blood cells located in the lymphatic system, which is part of the body’s immune system. CLL typically starts in white blood cells located in the bone marrow and then moves into the bloodstream.
topMIND
What is topMIND?
This is a Phase 1b/2a trial investigating a possible treatment combination for patients with non-Hodgkin lymphoma (NHL) or chronic lymphocytic leukemia (CLL) who have already tried other treatment options.
What drugs are being studied?
There are 2 drugs being studied in this trial. The first drug is called tafasitamab. The second drug is called parsaclisib. All of the participants in this trial will receive both of these drugs as combination therapy.
What are the main goals of the trial?
The main goals of the trial are to learn about the safety and efficacy of this combination. The trial doctors will keep track of the participants’ overall health during the trial and help manage any medical problems they might have while taking the treatment combination. They will also keep track of how each participant’s cancer responds to the treatment
Eligibility Criteria
- Over 18 years old This trial is for people over 18 years old
- Relapsed NHL or CLL This trial is for people with NHL or CLL that has come back (relapsed) or that did not respond to previous treatment (refractory)
- Have tried 2 other treatments All of the participants in this trial have a certain type of NHL or CLL and have tried at least 2 other treatments for their cancer.
Where to join
You will need to travel to one of the study clinics taking part in this clinical trial. Sites are located in:
Location
Status
Location
CANCER CENTER FOR BLOOD DISORDERS
BETHESDA, MD, US, 20817
Status
Completed
Location
HOSPITAL UNIVERSITARIO QUIRONSALUD MADRID
MADRID, Spain, 28223
Status
Recruiting
Location
HOSPITAL UNIVERSITARIO 12 DE OCTUBRE
MADRID, Spain, 28041
Status
Recruiting
Location
HOSPITAL UNIVERSITARIO MARQUES DE VALDECILLA
SANTANDER, Spain, 39008
Status
Recruiting
Location
IRCCS ISTITUTO CLINICO HUMANITAS
ROZZANO, Italy, 20089
Status
Recruiting
Location
UNIVERSITY OF SOUTHERN CALIFORNIA
LOS ANGELES, CA, US, 90089
Status
Recruiting
inMIND
What is inMIND?
This is a Phase 3 trial investigating a possible treatment strategy for patients with certain types of non-Hodgkin lymphoma (NHL) who have already tried at least 1 other treatment option.
What drugs are being studied?
The drug being studied is called tafasitamab. Researchers want to learn whether adding tafasitamab to an NHL treatment regimen will help improve patient outcomes.
What are the main goals of the trial?
The main goal of the trial is to learn whether adding tafasitamab to a patient’s treatment regimen might offer clinical benefits. The trial researchers will measure “progression-free survival (PFS),” which is how long a patient stays on treatment before their cancer gets worse. They will compare PFS times for patients who receive tafasitamab with PFS times for patients who receive the placebo.
Eligibility Criteria
- Over 18 years old This trial is for people over 18 years old
- People with FL or MZL This trial is for people follicular lymphoma (FL) or marginal zone lymphoma (MZL). Both of these are types of NHL.
- Have tried at least 1 treatment The participants in this trial have tried at least 1 other treatment option for their NHL, but their cancer came back (relapsed) or did not respond to the treatment (refractory).
Where to join
You will need to travel to one of the study clinics taking part in this clinical trial. Sites are located in:
Trial Locations
Location
Status
Location
RENOVATIO CLINICAL
SPRING, TX, US, 77380
Status
Completed
Location
CANCER CENTER FOR BLOOD DISORDERS
BETHESDA, MD, US, 20817
Status
Recruiting
Location
NORTHWEST MEDICAL SPECIALTIES PLLC
TACOMA, WA, US, 98405
Status
Recruiting
Location
ASCLEPES RESEARCH CENTERS
WEEKI WACHEE, FL, US, 34607
Status
Recruiting
Location
BRCR MEDICAL CENTER, INC
PLANTATION, FL, US, 33322
Status
Recruiting
Location
VISTA ONCOLOGY INC PS
OLYMPIA, WA, US, 98506
Status
Recruiting
JOIN THE INCYTE COMMUNITY
INNOVATING FOR TOMORROW
Join the Incyte Community to receive updates on news about Incyte, including information on newly enrolling trials. The Incyte Community enables you to stay informed & prepared to contribute to research you care about. Please review the Privacy Policy to understand how your information will be collected and processed. If you provide information about another person, by providing that information you certify that you have their authorization to share their personal information.
Join us in our journey as we continue to Solve On.
1/3
Participant Information
Please fill in the form below if you would like to stay in touch regarding ongoing and newly enrolling trials.
Fields marked with asterisk (*) are mandatory.
